PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from AbbVie Inc. Supported, in part, by an educational grant from Ferring Pharmaceuticals, Inc. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

MODERATOR

Aline Charabaty, MD, AGAF, FACG (Chair) Associate Professor of Medicine Johns Hopkins School of Medicine Clinical Director, GI Division Director, IBD Center Sibley Memorial Hospital Washington, District of Columbia

SCHEDULE

#MondayNightIBD takes place on Mondays at 4 PM Eastern Time. You can join the conversation at https://twitter.com/MondayNightIBD

[table id=66 /]

PROGRAM OVERVIEW

Despite an increased understanding of inflammatory bowel diseases (IBD) pathophysiology and the introduction of corresponding targeted treatments with the potential to alter the disease’s natural history, clinical and endoscopic remission remain elusive for many patients. Several factors contribute to suboptimal outcomes, including an entrenched treatment paradigm that frequently results in prolonged use of ineffective medications, uncertainty about the safety and efficacy of medications, systemic barriers, and access challenges. In order to effectively treat IBD, gastroenterologists and the multidisciplinary IBD team of clinicians need strong foundational knowledge of the broad range of therapeutic agents licensed for the induction and maintenance of disease control, and how to individualize their use for any given patient. Education is necessary to ensure that clinicians who manage patients with IBD are up-to-date on current management strategies, including the use of objective measures such as mucosal healing and deep remission; new and emerging therapies, particularly novel mechanisms of action and safety profiles; and recent data from clinical trials. Clinicians must be knowledgeable regarding the benefits of early intervention, top-down versus step-up approaches, strategies for attaining remission and reducing healthcare costs, and new treat-to-target recommendations for management. This program will reduce these gaps through a conversational-style venue that fosters deeper educational impact and ultimately improves patient care.

TARGET AUDIENCE

This educational initiative has been designed for gastroenterologists, gastroenterologists in training, surgeons, subspecialists such as dieticians and psychologists, nurse practitioners, physician assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

Target objective measures of disease activity to prevent disease progression, bowel damage, and disability in patients with IBD
Interpret guideline-directed strategies and best practices for the care of patients with IBD
Outline strategies for the management of complex IBD cases
Utilize clinical trial and real-world data on approved treatments to personalize therapy and prevent disease progression, bowel damage, and disability in patients with IBD
Evaluate pivotal clinical trial data and real-world studies of new and emerging agents for the treatment of IBD
Determine appropriate positioning of therapies in the management of IBD
Employ a management plan that incorporates strategies and validated tools for improving patient education, ascertaining patient preferences, and aligning provider and patient treatment goals
Illustrate the importance of patient-centered care in addressing burdens associated with IBD including optimizing health maintenance measures
Recognize the importance of a multidisciplinary approach to care in managing patients with IBD
Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest, study the educational activity, and complete the posttest
Complete the evaluation form

A statement of credit will be issued only upon completion of the steps above, including receipt of a completed activity evaluation form.

MEDIA

Internet

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education and MondayNightIBD. Integrity Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live material for a maximum of 25.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty have reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities as listed in the Schedule section of this page. Aline Charabaty, MD, AGAF, FACG Consulting Fees: AbbVie, Janssen, Pfizer, Takeda The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended. For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

@MondayNightIBD Case Conversations: Managing the IBD Patient